Bio Blast Pharma prices IPO at $11, the low end of the range

By Renaissance Capital,

Shutterstock photo

Bio Blast Pharma, a biotech developing treatments for rare and ultra-rare genetic diseases, raised $35 million by offering 3.2 million shares at $11, the low end of the range of $11 to $13. Bio Blast Pharma plans to list on the NASDAQ under the symbol ORPN. Oppenheimer & Co. and Roth Capital acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: ORPN

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by